081 Long-term safety with sarilumab plus conventional synthetic disease-modifying antirheumatic drugs and sarilumab monotherapy in rheumatoid arthritis: an integrated analysis with 9, 000 patient-years of follow-up. (12th April 2019) - Fleischmann, Roy